Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
| Registry | NCT03496831 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 7500 (Estimated) |
| Sponsor | Simon Krabbe (Other); collaborators: University of Aarhus, Zealand University Hospital, University of Southern Denmark |
| Conditions | Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis |
| Interventions | Biologic Agents (Drug) |
| Dates | start 2006-01-01, primary completion 2017-12-31, completion 2017-12-31, first posted 2018-04-12, last updated 2018-04-17 |
Related Papers Related Patents Related Grants Related Experts
All trials for Rheumatoid Arthritis All trials for Spondyloarthritis All trials of Biologic Agents
Background The risk for hospitalized infection (i.e. infection leading to hospitalization) in patients with inflammatory arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with biological drugs is known to be increased compared to the background population. In daily clinical practice, there is a need for a simple way to assess the absolute risk for hospitalized infection in individual patients based on easily available information such as age, diagnosis, functional status, comorbidities and medication. This risk estimate will be useful in clinical decision making e.g. when advising patients on whether or not to initiate biologic therapy or when advising patients on influenza or pneumococcal vaccination.
Objectives The objectives are 1) to assess the risk for hospitalized infection (infection leading to hospitalization) in patients with inflammatory arthritis during 12 months of follow-up after initiating treatment with their first biological drug (bDMARD) with the risk in the general population, and 2) to develop a simple, clinically useful algorithm that allows prediction of the risk of hospitalized infection in individual patients.
Methods Observational cohort study based on existing data in: The Danish Rheumatology Register (DANBIO), The Danish National Patient Register, The Danish National Prescription Register and The Danish Register of Causes of Death. All patients registered in DANBIO with RA, PsA or axSpA who initiated treatment with their first biological drug between January 1, 2006 and December 31, 2016 will be identified. Baseline predictors and outcomes (hospitalized infection or death) during 12 months of follow-up are obtained. Logistic regression analysis and 10-fold cross-validation will be used to develop and internally validate the prediction model.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Rheumatoid Arthritis | Drug: Biologic Agents | Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9. | |
| Spondyloarthritis | Drug: Biologic Agents | Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9. | |
| Psoriatic Arthritis | Drug: Biologic Agents | Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2. |
Sex: All, ages: 18 Years to any
Inclusion criteria: * Patients with RA: Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9. * Patients with SpA: Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9. * Patients with PsA: Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2. * First bDMARD treatment course. * Start of treatment with first bDMARD in the period January 1, 2006 to December 31, 2016. * Age at start of treatment with first bDMARD ≥ 18 years. Exclusion criteria: \- Not followed in DANBIO since start of first bDMARD.